Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login

Research Library

A-Z Conditions  Participate in ORR

Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease

  • Journal : Recent Patents on CNS Drug Discovery
  • Publication Year : 2012
  • Authors : Onintza Sagredo, M. Ruth Pazos, Sara Valdeolivas, & Javier Fernández-Ruiz

Abstract:

 

Cannabinoid pharmacology has experienced a notable increase in the last 3 decades which is allowing the development of novel cannabinoid-based medicines for the treatment of different human pathologies, for example, Ce- samet (nabilone) or Marinol (synthetic 9-tetrahydrocannabinol for oral administration) that were approved in 80s for the treatment of nausea and vomiting associated with chemotherapy treatment in cancer patients and in 90s for anorexia- cachexia associated with AIDS therapy. Recently, the British company GW Pharmaceuticals plc has developed an oromucosal spray called Sativex, which is constituted by an equimolecular combination of 9-tetrahydrocannabinol- and can- nabidiol-enriched botanical extracts. Sativex has been approved for the treatment of specific symptoms (i.e. spasticity and pain) of multiple sclerosis patients in various countries (i.e. Canada, UK, Spain, New Zealand). However, this canna- bis-based medicine has been also proposed to be useful in other neurological disorders given the analgesic, antitumoral, anti-inflammatory, and neuroprotective properties of their components demonstrated in preclinical models. Numerous clinical trials are presently being conducted to confirm this potential in patients. We are particularly interested in the case of Huntington’s disease (HD), an autosomal-dominant inherited disorder caused by an excess of CAG repeats in the genomic allele resulting in a polyQ expansion in the encoded protein called Huntington, and that affects primarily stratal and cortical neurons thus producing motor abnormalities (i.e. chorea) and dementia. Cannabinoids have been studied for alleviation of hyperkinetic symptoms, given their inhibitory effects on movement, and, in particular, as disease-modifying agents due to their anti-inflammatory, neuroprotective and neuroregenerative properties. This potential has been corroborated in different experimental models of HD and using different types of cannabinoid agonists, including the phytocannabinoids present in Sativex, and we are close to initiate a clinical trial with this cannabis-based medicine to evaluate its capability as a disease-modifying agent in a population of HD patients. The present review will address all preclinical evidence supporting the potential of Sativex for the treatment of disease progression in HD patients. The article presents some promising patents on the cannabinoids.

Read the Full Article

Share This:

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
PrevPreviousMedical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically
NextCB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioidsNext

Conditions:

  • Huntington's Disease

Research Information:

Research Keywords:

  • ∆9-tetrahydrocannabinol (THC), Cannabinoid/s

Search the Research Library >

Follow Us:

Facebook Twitter Youtube

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • PO Box 15224, Colorado Springs, CO 80935
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2024 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer

Open the following in new tabs if you:

If you are already a user: Client Login

If you are not, then register: Client Registration

Once Logged in, click below to refresh the page.